Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158332 | 0.88 | NPC1 (0.39) | MAPTPKMEPHX1KDM1A | |
| SCHEMBL5158974 | 0.88 | MAPT (0.39) | MAPTPKMKDM1ATACR1 | |
| SCHEMBL6481103 | 0.86 | MAPT (0.40) | MAPTPKMEPHX1KDM1ATACR1 | |
| SCHEMBL5202490 | 0.84 | HPGD (0.42) | MAPTPKMKDM1ACCR5 | |
| SCHEMBL5159003 | 0.79 | MAPT (0.46) | MAPTPKMKDM1ACCR5MAOB | |
| SCHEMBL6508972 | 0.76 | KMT2A (0.51) | EPHX1 | |
| SCHEMBL5156709 | 0.76 | MAPT (0.44) | MAPTPKMKDM1AMAOBTACR1 | |
| SCHEMBL5176933 | 0.74 | MAPT (0.43) | MAPTPKMKDM1AMAOBTACR1 | |
| SCHEMBL1095613 | 0.74 | MAPT (0.49) | MAPTPKMKDM1ACCR5MAOB | |
| SCHEMBL27437633 | 0.73 | EPHX1 (0.56) | PKMEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | MAPT 2851/4885PKM 609/4885EPHX1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.